A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ ) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors

Brief description of study

The purpose of the study to determine the efficacy of TJ004309 (anti- CD-73 ab )in combination with atezolizumab (PDL-1 inhibitor) immunotherapy in patients with advanced or metastatic solid tumors. We want to know how patients respond per each tumor type, any adverse events, and laboratory value abnormalities. The study drug combination is investigational, which means that the study drug and combination have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this combination in the current trial.

Clinical Study Identifier: s21-00969
ClinicalTrials.gov Identifier: NCT05001347

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.